Last reviewed · How we verify

Paracetamol 1% solution

Baxter Healthcare Corporation · Phase 3 active Small molecule

Paracetamol inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.

Paracetamol inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. Used for Mild to moderate pain, Fever reduction.

At a glance

Generic nameParacetamol 1% solution
SponsorBaxter Healthcare Corporation
Drug classAnalgesic and antipyretic
TargetCyclooxygenase (COX), primarily central nervous system isoforms
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Paracetamol (acetaminophen) works primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production and thereby lowering pain perception and body temperature set point. Unlike NSAIDs, it has minimal peripheral anti-inflammatory effects and does not significantly inhibit COX in peripheral tissues, making it safer for gastrointestinal and cardiovascular systems at therapeutic doses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: